nodes	percent_of_prediction	percent_of_DWPC	metapath
Mirabegron—ORM1—Vismodegib—skin cancer	0.217	0.256	CbGbCtD
Mirabegron—ORM1—Vemurafenib—skin cancer	0.172	0.202	CbGbCtD
Mirabegron—ALB—Vismodegib—skin cancer	0.0913	0.108	CbGbCtD
Mirabegron—ALB—Vemurafenib—skin cancer	0.0722	0.0852	CbGbCtD
Mirabegron—ABCB1—Vismodegib—skin cancer	0.0478	0.0564	CbGbCtD
Mirabegron—CYP3A4—Temozolomide—skin cancer	0.0413	0.0487	CbGbCtD
Mirabegron—CYP3A4—Imiquimod—skin cancer	0.0413	0.0487	CbGbCtD
Mirabegron—CYP2D6—Vemurafenib—skin cancer	0.0356	0.042	CbGbCtD
Mirabegron—ALB—Fluorouracil—skin cancer	0.0324	0.0383	CbGbCtD
Mirabegron—CYP3A4—Vismodegib—skin cancer	0.0286	0.0338	CbGbCtD
Mirabegron—ABCB1—Dactinomycin—skin cancer	0.0251	0.0296	CbGbCtD
Mirabegron—CYP3A4—Vemurafenib—skin cancer	0.0226	0.0267	CbGbCtD
Mirabegron—ABCB1—Docetaxel—skin cancer	0.013	0.0153	CbGbCtD
Mirabegron—CYP3A4—Docetaxel—skin cancer	0.00777	0.00916	CbGbCtD
Mirabegron—Rash papular—Vemurafenib—skin cancer	0.00562	0.0369	CcSEcCtD
Mirabegron—Lung neoplasm malignant—Docetaxel—skin cancer	0.00355	0.0233	CcSEcCtD
Mirabegron—Eyelid oedema—Imiquimod—skin cancer	0.00354	0.0232	CcSEcCtD
Mirabegron—Gamma-glutamyltransferase increased—Vemurafenib—skin cancer	0.00255	0.0167	CcSEcCtD
Mirabegron—Breast disorder—Vismodegib—skin cancer	0.00222	0.0146	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Vismodegib—skin cancer	0.00222	0.0145	CcSEcCtD
Mirabegron—Breast cancer—Docetaxel—skin cancer	0.00195	0.0128	CcSEcCtD
Mirabegron—Neoplasm—Vemurafenib—skin cancer	0.00189	0.0124	CcSEcCtD
Mirabegron—Vaginal infection—Imiquimod—skin cancer	0.00169	0.0111	CcSEcCtD
Mirabegron—Connective tissue disorder—Vismodegib—skin cancer	0.00167	0.011	CcSEcCtD
Mirabegron—Atrial fibrillation—Vemurafenib—skin cancer	0.0016	0.0105	CcSEcCtD
Mirabegron—Back pain—Vismodegib—skin cancer	0.00143	0.00941	CcSEcCtD
Mirabegron—Atrial fibrillation—Imiquimod—skin cancer	0.00137	0.00898	CcSEcCtD
Mirabegron—Purpura—Imiquimod—skin cancer	0.00135	0.00883	CcSEcCtD
Mirabegron—Cerebrovascular accident—Imiquimod—skin cancer	0.00132	0.00869	CcSEcCtD
Mirabegron—Gamma-glutamyltransferase increased—Temozolomide—skin cancer	0.0013	0.00854	CcSEcCtD
Mirabegron—Arthralgia—Vismodegib—skin cancer	0.00126	0.00828	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Vismodegib—skin cancer	0.00125	0.00823	CcSEcCtD
Mirabegron—Cystitis noninfective—Bleomycin—skin cancer	0.00124	0.00814	CcSEcCtD
Mirabegron—Urinary retention—Imiquimod—skin cancer	0.00123	0.00809	CcSEcCtD
Mirabegron—Cystitis—Bleomycin—skin cancer	0.00123	0.00804	CcSEcCtD
Mirabegron—Skin disorder—Vismodegib—skin cancer	0.00117	0.00771	CcSEcCtD
Mirabegron—Breast disorder—Imiquimod—skin cancer	0.00117	0.00769	CcSEcCtD
Mirabegron—Infestation NOS—Vemurafenib—skin cancer	0.00117	0.00769	CcSEcCtD
Mirabegron—Infestation—Vemurafenib—skin cancer	0.00117	0.00769	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Vemurafenib—skin cancer	0.00116	0.00763	CcSEcCtD
Mirabegron—Bladder pain—Bleomycin—skin cancer	0.00115	0.00753	CcSEcCtD
Mirabegron—Influenza—Imiquimod—skin cancer	0.00112	0.00736	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Vismodegib—skin cancer	0.0011	0.00723	CcSEcCtD
Mirabegron—Dyspepsia—Vismodegib—skin cancer	0.00106	0.00699	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Vismodegib—skin cancer	0.00104	0.00686	CcSEcCtD
Mirabegron—Fatigue—Vismodegib—skin cancer	0.00104	0.00685	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Imiquimod—skin cancer	0.00104	0.00684	CcSEcCtD
Mirabegron—Constipation—Vismodegib—skin cancer	0.00103	0.00679	CcSEcCtD
Mirabegron—Connective tissue disorder—Vemurafenib—skin cancer	0.00103	0.00679	CcSEcCtD
Mirabegron—Vaginal infection—Temozolomide—skin cancer	0.00101	0.00663	CcSEcCtD
Mirabegron—Infestation NOS—Imiquimod—skin cancer	0.000999	0.00656	CcSEcCtD
Mirabegron—Infestation—Imiquimod—skin cancer	0.000999	0.00656	CcSEcCtD
Mirabegron—Erythema multiforme—Vemurafenib—skin cancer	0.000995	0.00653	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Imiquimod—skin cancer	0.000991	0.0065	CcSEcCtD
Mirabegron—Gastrointestinal pain—Vismodegib—skin cancer	0.000989	0.00649	CcSEcCtD
Mirabegron—Dry eye—Temozolomide—skin cancer	0.000989	0.00649	CcSEcCtD
Mirabegron—Eye disorder—Vemurafenib—skin cancer	0.000983	0.00645	CcSEcCtD
Mirabegron—Cardiac disorder—Vemurafenib—skin cancer	0.000976	0.00641	CcSEcCtD
Mirabegron—Urinary tract infection—Imiquimod—skin cancer	0.000971	0.00638	CcSEcCtD
Mirabegron—Neoplasm—Temozolomide—skin cancer	0.000968	0.00635	CcSEcCtD
Mirabegron—Abdominal pain—Vismodegib—skin cancer	0.000956	0.00628	CcSEcCtD
Mirabegron—Cerebrovascular accident—Bleomycin—skin cancer	0.00094	0.00617	CcSEcCtD
Mirabegron—Sinusitis—Imiquimod—skin cancer	0.000938	0.00615	CcSEcCtD
Mirabegron—Rhinitis—Imiquimod—skin cancer	0.000899	0.0059	CcSEcCtD
Mirabegron—Urinary tract disorder—Imiquimod—skin cancer	0.000886	0.00582	CcSEcCtD
Mirabegron—Back pain—Vemurafenib—skin cancer	0.000886	0.00581	CcSEcCtD
Mirabegron—Connective tissue disorder—Imiquimod—skin cancer	0.000882	0.00579	CcSEcCtD
Mirabegron—Urethral disorder—Imiquimod—skin cancer	0.000879	0.00577	CcSEcCtD
Mirabegron—Vascular purpura—Temozolomide—skin cancer	0.000869	0.0057	CcSEcCtD
Mirabegron—Asthenia—Vismodegib—skin cancer	0.000868	0.0057	CcSEcCtD
Mirabegron—Pruritus—Vismodegib—skin cancer	0.000856	0.00562	CcSEcCtD
Mirabegron—Erythema multiforme—Imiquimod—skin cancer	0.000848	0.00557	CcSEcCtD
Mirabegron—Eye disorder—Imiquimod—skin cancer	0.000838	0.0055	CcSEcCtD
Mirabegron—Diarrhoea—Vismodegib—skin cancer	0.000828	0.00543	CcSEcCtD
Mirabegron—Purpura—Temozolomide—skin cancer	0.000806	0.00529	CcSEcCtD
Mirabegron—Arthralgia—Vemurafenib—skin cancer	0.00078	0.00512	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Vemurafenib—skin cancer	0.000774	0.00508	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Dactinomycin—skin cancer	0.000774	0.00508	CcSEcCtD
Mirabegron—Rash—Vismodegib—skin cancer	0.000763	0.00501	CcSEcCtD
Mirabegron—Dermatitis—Vismodegib—skin cancer	0.000762	0.005	CcSEcCtD
Mirabegron—Back pain—Imiquimod—skin cancer	0.000755	0.00496	CcSEcCtD
Mirabegron—Infection—Vemurafenib—skin cancer	0.000742	0.00487	CcSEcCtD
Mirabegron—Skin disorder—Vemurafenib—skin cancer	0.000726	0.00477	CcSEcCtD
Mirabegron—Nausea—Vismodegib—skin cancer	0.000719	0.00472	CcSEcCtD
Mirabegron—Osteoarthritis—Fluorouracil—skin cancer	0.000716	0.0047	CcSEcCtD
Mirabegron—Blood pressure increased—Docetaxel—skin cancer	0.000712	0.00467	CcSEcCtD
Mirabegron—Breast disorder—Temozolomide—skin cancer	0.000702	0.00461	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Temozolomide—skin cancer	0.0007	0.00459	CcSEcCtD
Mirabegron—Palpitations—Imiquimod—skin cancer	0.00069	0.00453	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Temozolomide—skin cancer	0.000685	0.0045	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Vemurafenib—skin cancer	0.000681	0.00447	CcSEcCtD
Mirabegron—Abdominal distension—Temozolomide—skin cancer	0.000676	0.00444	CcSEcCtD
Mirabegron—Hypertension—Imiquimod—skin cancer	0.000674	0.00443	CcSEcCtD
Mirabegron—Arthralgia—Imiquimod—skin cancer	0.000665	0.00436	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Imiquimod—skin cancer	0.00066	0.00433	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Dactinomycin—skin cancer	0.000656	0.00431	CcSEcCtD
Mirabegron—Dry mouth—Imiquimod—skin cancer	0.00065	0.00427	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Vemurafenib—skin cancer	0.000645	0.00424	CcSEcCtD
Mirabegron—Fatigue—Vemurafenib—skin cancer	0.000644	0.00423	CcSEcCtD
Mirabegron—Neoplasm—Docetaxel—skin cancer	0.000644	0.00423	CcSEcCtD
Mirabegron—Nasopharyngitis—Fluorouracil—skin cancer	0.00064	0.0042	CcSEcCtD
Mirabegron—Constipation—Vemurafenib—skin cancer	0.000639	0.0042	CcSEcCtD
Mirabegron—Infection—Imiquimod—skin cancer	0.000633	0.00416	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Temozolomide—skin cancer	0.000624	0.0041	CcSEcCtD
Mirabegron—Tachycardia—Imiquimod—skin cancer	0.000622	0.00408	CcSEcCtD
Mirabegron—Skin disorder—Imiquimod—skin cancer	0.000619	0.00406	CcSEcCtD
Mirabegron—Infestation NOS—Temozolomide—skin cancer	0.000599	0.00393	CcSEcCtD
Mirabegron—Infestation—Temozolomide—skin cancer	0.000599	0.00393	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Temozolomide—skin cancer	0.000594	0.0039	CcSEcCtD
Mirabegron—Urinary tract infection—Temozolomide—skin cancer	0.000582	0.00382	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Imiquimod—skin cancer	0.000581	0.00381	CcSEcCtD
Mirabegron—Upper respiratory tract infection—Fluorouracil—skin cancer	0.000575	0.00378	CcSEcCtD
Mirabegron—Erythema multiforme—Dactinomycin—skin cancer	0.000562	0.00369	CcSEcCtD
Mirabegron—Sinusitis—Temozolomide—skin cancer	0.000562	0.00369	CcSEcCtD
Mirabegron—Dyspepsia—Imiquimod—skin cancer	0.000561	0.00368	CcSEcCtD
Mirabegron—Infestation NOS—Fluorouracil—skin cancer	0.000552	0.00362	CcSEcCtD
Mirabegron—Infestation—Fluorouracil—skin cancer	0.000552	0.00362	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Imiquimod—skin cancer	0.00055	0.00361	CcSEcCtD
Mirabegron—Fatigue—Imiquimod—skin cancer	0.000549	0.00361	CcSEcCtD
Mirabegron—Atrial fibrillation—Docetaxel—skin cancer	0.000545	0.00358	CcSEcCtD
Mirabegron—Urinary tract infection—Fluorouracil—skin cancer	0.000536	0.00352	CcSEcCtD
Mirabegron—Asthenia—Vemurafenib—skin cancer	0.000536	0.00352	CcSEcCtD
Mirabegron—Urinary tract disorder—Temozolomide—skin cancer	0.000531	0.00349	CcSEcCtD
Mirabegron—Pruritus—Vemurafenib—skin cancer	0.000529	0.00347	CcSEcCtD
Mirabegron—Connective tissue disorder—Temozolomide—skin cancer	0.000528	0.00347	CcSEcCtD
Mirabegron—Urethral disorder—Temozolomide—skin cancer	0.000527	0.00346	CcSEcCtD
Mirabegron—Gastrointestinal pain—Imiquimod—skin cancer	0.000521	0.00342	CcSEcCtD
Mirabegron—Sinusitis—Fluorouracil—skin cancer	0.000518	0.0034	CcSEcCtD
Mirabegron—Diarrhoea—Vemurafenib—skin cancer	0.000511	0.00336	CcSEcCtD
Mirabegron—Erythema multiforme—Temozolomide—skin cancer	0.000508	0.00334	CcSEcCtD
Mirabegron—Urticaria—Imiquimod—skin cancer	0.000506	0.00332	CcSEcCtD
Mirabegron—Abdominal pain—Imiquimod—skin cancer	0.000504	0.00331	CcSEcCtD
Mirabegron—Eye disorder—Temozolomide—skin cancer	0.000502	0.0033	CcSEcCtD
Mirabegron—Cardiac disorder—Temozolomide—skin cancer	0.000499	0.00328	CcSEcCtD
Mirabegron—Rhinitis—Fluorouracil—skin cancer	0.000497	0.00326	CcSEcCtD
Mirabegron—Dizziness—Vemurafenib—skin cancer	0.000494	0.00324	CcSEcCtD
Mirabegron—Rash—Vemurafenib—skin cancer	0.000471	0.00309	CcSEcCtD
Mirabegron—Dermatitis—Vemurafenib—skin cancer	0.000471	0.00309	CcSEcCtD
Mirabegron—Headache—Vemurafenib—skin cancer	0.000468	0.00307	CcSEcCtD
Mirabegron—Breast disorder—Docetaxel—skin cancer	0.000467	0.00307	CcSEcCtD
Mirabegron—Aspartate aminotransferase increased—Docetaxel—skin cancer	0.000465	0.00305	CcSEcCtD
Mirabegron—Nasopharyngitis—Docetaxel—skin cancer	0.000462	0.00303	CcSEcCtD
Mirabegron—Asthenia—Imiquimod—skin cancer	0.000457	0.003	CcSEcCtD
Mirabegron—Alanine aminotransferase increased—Docetaxel—skin cancer	0.000456	0.00299	CcSEcCtD
Mirabegron—Back pain—Temozolomide—skin cancer	0.000453	0.00297	CcSEcCtD
Mirabegron—Pruritus—Imiquimod—skin cancer	0.000451	0.00296	CcSEcCtD
Mirabegron—Infection—Bleomycin—skin cancer	0.00045	0.00295	CcSEcCtD
Mirabegron—Nausea—Vemurafenib—skin cancer	0.000444	0.00291	CcSEcCtD
Mirabegron—Vision blurred—Temozolomide—skin cancer	0.000441	0.0029	CcSEcCtD
Mirabegron—Diarrhoea—Imiquimod—skin cancer	0.000436	0.00286	CcSEcCtD
Mirabegron—Dizziness—Imiquimod—skin cancer	0.000421	0.00277	CcSEcCtD
Mirabegron—Infection—Dactinomycin—skin cancer	0.00042	0.00275	CcSEcCtD
Mirabegron—Palpitations—Temozolomide—skin cancer	0.000414	0.00271	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Bleomycin—skin cancer	0.000413	0.00271	CcSEcCtD
Mirabegron—Vision blurred—Fluorouracil—skin cancer	0.000406	0.00267	CcSEcCtD
Mirabegron—Hypertension—Temozolomide—skin cancer	0.000404	0.00265	CcSEcCtD
Mirabegron—Rash—Imiquimod—skin cancer	0.000402	0.00264	CcSEcCtD
Mirabegron—Dermatitis—Imiquimod—skin cancer	0.000401	0.00264	CcSEcCtD
Mirabegron—Headache—Imiquimod—skin cancer	0.000399	0.00262	CcSEcCtD
Mirabegron—Arthralgia—Temozolomide—skin cancer	0.000398	0.00262	CcSEcCtD
Mirabegron—Infestation NOS—Docetaxel—skin cancer	0.000398	0.00261	CcSEcCtD
Mirabegron—Infestation—Docetaxel—skin cancer	0.000398	0.00261	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Temozolomide—skin cancer	0.000396	0.0026	CcSEcCtD
Mirabegron—Stevens-Johnson syndrome—Docetaxel—skin cancer	0.000395	0.00259	CcSEcCtD
Mirabegron—Dry mouth—Temozolomide—skin cancer	0.00039	0.00256	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Dactinomycin—skin cancer	0.000385	0.00253	CcSEcCtD
Mirabegron—Infection—Temozolomide—skin cancer	0.000379	0.00249	CcSEcCtD
Mirabegron—Nausea—Imiquimod—skin cancer	0.000379	0.00249	CcSEcCtD
Mirabegron—Skin disorder—Temozolomide—skin cancer	0.000371	0.00244	CcSEcCtD
Mirabegron—Fatigue—Dactinomycin—skin cancer	0.000364	0.00239	CcSEcCtD
Mirabegron—Urticaria—Bleomycin—skin cancer	0.00036	0.00236	CcSEcCtD
Mirabegron—Rhinitis—Docetaxel—skin cancer	0.000358	0.00235	CcSEcCtD
Mirabegron—Urinary tract disorder—Docetaxel—skin cancer	0.000353	0.00232	CcSEcCtD
Mirabegron—Connective tissue disorder—Docetaxel—skin cancer	0.000351	0.00231	CcSEcCtD
Mirabegron—Urethral disorder—Docetaxel—skin cancer	0.00035	0.0023	CcSEcCtD
Mirabegron—Infection—Fluorouracil—skin cancer	0.00035	0.0023	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Temozolomide—skin cancer	0.000348	0.00228	CcSEcCtD
Mirabegron—Gastrointestinal pain—Dactinomycin—skin cancer	0.000345	0.00227	CcSEcCtD
Mirabegron—Tachycardia—Fluorouracil—skin cancer	0.000343	0.00225	CcSEcCtD
Mirabegron—Erythema multiforme—Docetaxel—skin cancer	0.000338	0.00222	CcSEcCtD
Mirabegron—Dyspepsia—Temozolomide—skin cancer	0.000336	0.00221	CcSEcCtD
Mirabegron—Eye disorder—Docetaxel—skin cancer	0.000334	0.00219	CcSEcCtD
Mirabegron—Abdominal pain—Dactinomycin—skin cancer	0.000334	0.00219	CcSEcCtD
Mirabegron—Cardiac disorder—Docetaxel—skin cancer	0.000332	0.00218	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Temozolomide—skin cancer	0.00033	0.00216	CcSEcCtD
Mirabegron—Fatigue—Temozolomide—skin cancer	0.000329	0.00216	CcSEcCtD
Mirabegron—Constipation—Temozolomide—skin cancer	0.000327	0.00214	CcSEcCtD
Mirabegron—Asthenia—Bleomycin—skin cancer	0.000325	0.00213	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Fluorouracil—skin cancer	0.000321	0.0021	CcSEcCtD
Mirabegron—Pruritus—Bleomycin—skin cancer	0.00032	0.0021	CcSEcCtD
Mirabegron—Gastrointestinal pain—Temozolomide—skin cancer	0.000312	0.00205	CcSEcCtD
Mirabegron—Dyspepsia—Fluorouracil—skin cancer	0.00031	0.00203	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Fluorouracil—skin cancer	0.000304	0.00199	CcSEcCtD
Mirabegron—Urticaria—Temozolomide—skin cancer	0.000303	0.00199	CcSEcCtD
Mirabegron—Asthenia—Dactinomycin—skin cancer	0.000303	0.00199	CcSEcCtD
Mirabegron—Abdominal pain—Temozolomide—skin cancer	0.000302	0.00198	CcSEcCtD
Mirabegron—Back pain—Docetaxel—skin cancer	0.000301	0.00198	CcSEcCtD
Mirabegron—Diarrhoea—Dactinomycin—skin cancer	0.000289	0.0019	CcSEcCtD
Mirabegron—Rash—Bleomycin—skin cancer	0.000285	0.00187	CcSEcCtD
Mirabegron—Dermatitis—Bleomycin—skin cancer	0.000285	0.00187	CcSEcCtD
Mirabegron—Urticaria—Fluorouracil—skin cancer	0.00028	0.00184	CcSEcCtD
Mirabegron—Palpitations—Docetaxel—skin cancer	0.000275	0.00181	CcSEcCtD
Mirabegron—Asthenia—Temozolomide—skin cancer	0.000274	0.0018	CcSEcCtD
Mirabegron—Pruritus—Temozolomide—skin cancer	0.00027	0.00177	CcSEcCtD
Mirabegron—Nausea—Bleomycin—skin cancer	0.000269	0.00177	CcSEcCtD
Mirabegron—Hypertension—Docetaxel—skin cancer	0.000269	0.00176	CcSEcCtD
Mirabegron—Rash—Dactinomycin—skin cancer	0.000266	0.00175	CcSEcCtD
Mirabegron—Arthralgia—Docetaxel—skin cancer	0.000265	0.00174	CcSEcCtD
Mirabegron—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—skin cancer	0.000263	0.00173	CcSEcCtD
Mirabegron—Diarrhoea—Temozolomide—skin cancer	0.000261	0.00172	CcSEcCtD
Mirabegron—Dry mouth—Docetaxel—skin cancer	0.000259	0.0017	CcSEcCtD
Mirabegron—Dizziness—Temozolomide—skin cancer	0.000253	0.00166	CcSEcCtD
Mirabegron—Infection—Docetaxel—skin cancer	0.000252	0.00166	CcSEcCtD
Mirabegron—Nausea—Dactinomycin—skin cancer	0.000251	0.00165	CcSEcCtD
Mirabegron—Pruritus—Fluorouracil—skin cancer	0.000249	0.00163	CcSEcCtD
Mirabegron—Tachycardia—Docetaxel—skin cancer	0.000248	0.00163	CcSEcCtD
Mirabegron—Skin disorder—Docetaxel—skin cancer	0.000247	0.00162	CcSEcCtD
Mirabegron—Rash—Temozolomide—skin cancer	0.000241	0.00158	CcSEcCtD
Mirabegron—Diarrhoea—Fluorouracil—skin cancer	0.000241	0.00158	CcSEcCtD
Mirabegron—Dermatitis—Temozolomide—skin cancer	0.000241	0.00158	CcSEcCtD
Mirabegron—Headache—Temozolomide—skin cancer	0.000239	0.00157	CcSEcCtD
Mirabegron—Dizziness—Fluorouracil—skin cancer	0.000233	0.00153	CcSEcCtD
Mirabegron—Musculoskeletal discomfort—Docetaxel—skin cancer	0.000231	0.00152	CcSEcCtD
Mirabegron—Nausea—Temozolomide—skin cancer	0.000227	0.00149	CcSEcCtD
Mirabegron—Dyspepsia—Docetaxel—skin cancer	0.000224	0.00147	CcSEcCtD
Mirabegron—Rash—Fluorouracil—skin cancer	0.000222	0.00146	CcSEcCtD
Mirabegron—Dermatitis—Fluorouracil—skin cancer	0.000222	0.00146	CcSEcCtD
Mirabegron—Headache—Fluorouracil—skin cancer	0.00022	0.00145	CcSEcCtD
Mirabegron—Gastrointestinal disorder—Docetaxel—skin cancer	0.000219	0.00144	CcSEcCtD
Mirabegron—Fatigue—Docetaxel—skin cancer	0.000219	0.00144	CcSEcCtD
Mirabegron—Constipation—Docetaxel—skin cancer	0.000217	0.00143	CcSEcCtD
Mirabegron—Nausea—Fluorouracil—skin cancer	0.000209	0.00137	CcSEcCtD
Mirabegron—Gastrointestinal pain—Docetaxel—skin cancer	0.000208	0.00136	CcSEcCtD
Mirabegron—Abdominal pain—Docetaxel—skin cancer	0.000201	0.00132	CcSEcCtD
Mirabegron—Asthenia—Docetaxel—skin cancer	0.000182	0.0012	CcSEcCtD
Mirabegron—Pruritus—Docetaxel—skin cancer	0.00018	0.00118	CcSEcCtD
Mirabegron—Diarrhoea—Docetaxel—skin cancer	0.000174	0.00114	CcSEcCtD
Mirabegron—Dizziness—Docetaxel—skin cancer	0.000168	0.0011	CcSEcCtD
Mirabegron—Rash—Docetaxel—skin cancer	0.00016	0.00105	CcSEcCtD
Mirabegron—Dermatitis—Docetaxel—skin cancer	0.00016	0.00105	CcSEcCtD
Mirabegron—Headache—Docetaxel—skin cancer	0.000159	0.00104	CcSEcCtD
Mirabegron—Nausea—Docetaxel—skin cancer	0.000151	0.00099	CcSEcCtD
